BridgeBio Oncology Therapeutics Inc. (BBOT) annual cash flow statement — 5-year operating, investing & financing history
| Cash from Operations | -172.07M | -113.89M | -763.82K | 0 | 0 | 0 |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | -132786.18% | -14811.1% | - | - | - | - |
| Net Income | -154.09M | -134.04M | 7.6M | -41.69K | -3.52K | -74 |
| Depreciation & Amortization | 977K | 610K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.82M | 5.87M | 271.57K | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -33.38M | 7.23M | -8.53M | 26.69K | 3.52K | 74 |
| Working Capital Changes | 10.61M | 6.43M | -104.61K | 15K | 0 | 0 |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 6.22M | -1.84M | 172.51K | 0 | 0 | 0 |
| Cash from Investing | -202.44M | 73.33M | -184M | 0 | 0 | 0 |
| Capital Expenditures | -861K | -606K | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 402.65M | 383.4M | 186.46M | 0 | 0 | 0 |
| Debt Issued (Net) | 373.46M | 0 | -209.85K | 0 | 0 | 0 |
| Equity Issued (Net) | 44.86M | 395.72M | 187.25M | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -15.66M | -12.32M | -578.55K | 0 | 0 | 0 |
| Net Change in Cash | 57.3M | 342.84M | 1.7M | 0 | 0 | 0 |
| Free Cash Flow | -172.93M | -114.5M | -763.82K | 0 | 0 | 0 |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | -329.8% | -14890.44% | - | - | - | - |
| FCF per Share | -5.55 | -3.68 | -0.05 | - | - | - |
| FCF Conversion (FCF/Net Income) | 1.12x | 0.85x | 0.01x | - | - | - |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying BBOT stock.
BridgeBio Oncology Therapeutics Inc. (BBOT) generated $-113.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
BridgeBio Oncology Therapeutics Inc. (BBOT) reported negative free cash flow of $114.5M in 2025, indicating capital requirements exceeded cash from operations.
BridgeBio Oncology Therapeutics Inc. (BBOT) spent $0.6M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.